1252779-95-5Relevant articles and documents
Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a "tail Switching" Strategy on a Piperazinyl Azetidine Skeleton
Chen, Zhen,Mori, Wakana,Deng, Xiaoyun,Cheng, Ran,Ogasawara, Daisuke,Zhang, Genwei,Schafroth, Michael A.,Dahl, Kenneth,Fu, Hualong,Hatori, Akiko,Shao, Tuo,Zhang, Yiding,Yamasaki, Tomoteru,Zhang, Xiaofei,Rong, Jian,Yu, Qingzhen,Hu, Kuan,Fujinaga, Masayuki,Xie, Lin,Kumata, Katsushi,Gou, Yuancheng,Chen, Jingjin,Gu, Shuyin,Bao, Liang,Wang, Lu,Collier, Thomas Lee,Vasdev, Neil,Shao, Yihan,Ma, Jun-An,Cravatt, Benjamin F.,Fowler, Christopher,Josephson, Lee,Zhang, Ming-Rong,Liang, Steven H.
, p. 3336 - 3353 (2019/03/29)
Monoacylglycerol lipase (MAGL) is a serine hydrolase that degrades 2-arachidonoylglycerol (2-AG) in the endocannabinoid system (eCB). Selective inhibition of MAGL has emerged as a potential therapeutic approach for the treatment of diverse pathological co
MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS
-
Page/Page column 34; 35, (2013/04/13)
Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.
